South Korea implements product pre-approval regulation

in-text-44861
New OTC derivatives will need approval

South Korea’s new derivatives testing system came into effect on June 13 in a bid to counter the bankruptcy of many small firms resulting from risky investments in foreign exchange derivatives during the financial crisis.

The New Product Approval (NPA) system requires financial investment companies, such as investment dealers and investment brokers, to receive pre-approval from the Korean Financial Investment Association (Kofia) for new over-the-counter derivatives. Korea is the first country to

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact [email protected] or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact [email protected] to find out more.

To continue reading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: